Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communicable Diseases | 2 | 2023 | 127 | 1.500 |
Why?
|
| Phaeohyphomycosis | 1 | 2022 | 1 | 0.820 |
Why?
|
| Cerebral Ventriculitis | 1 | 2022 | 3 | 0.820 |
Why?
|
| Central Nervous System Infections | 1 | 2022 | 36 | 0.780 |
Why?
|
| Enterobacter | 1 | 2021 | 7 | 0.770 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 49 | 0.770 |
Why?
|
| Alanine | 1 | 2022 | 105 | 0.760 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 33 | 0.740 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 224 | 0.720 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 192 | 0.680 |
Why?
|
| Bacteremia | 1 | 2021 | 160 | 0.670 |
Why?
|
| Bone Diseases, Infectious | 1 | 2019 | 8 | 0.660 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 437 | 0.660 |
Why?
|
| Sepsis | 2 | 2023 | 507 | 0.650 |
Why?
|
| Salmonella | 1 | 2019 | 54 | 0.640 |
Why?
|
| Myositis | 1 | 2019 | 44 | 0.640 |
Why?
|
| Salmonella Infections | 1 | 2019 | 50 | 0.630 |
Why?
|
| Arthritis | 1 | 2019 | 109 | 0.620 |
Why?
|
| Antiviral Agents | 2 | 2023 | 642 | 0.560 |
Why?
|
| Staphylococcus aureus | 2 | 2023 | 385 | 0.550 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 340 | 0.500 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 1472 | 0.430 |
Why?
|
| Dermatitis, Atopic | 2 | 2023 | 307 | 0.300 |
Why?
|
| Child | 10 | 2023 | 18408 | 0.280 |
Why?
|
| Meningitis, Haemophilus | 1 | 2023 | 6 | 0.220 |
Why?
|
| Lymphopenia | 1 | 2023 | 49 | 0.210 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2023 | 7 | 0.210 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 54 | 0.210 |
Why?
|
| Neutropenia | 1 | 2023 | 123 | 0.210 |
Why?
|
| Faculty | 1 | 2023 | 126 | 0.200 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2023 | 39 | 0.200 |
Why?
|
| Amphotericin B | 1 | 2022 | 28 | 0.200 |
Why?
|
| Ascomycota | 1 | 2022 | 27 | 0.200 |
Why?
|
| Deafness | 1 | 2023 | 77 | 0.200 |
Why?
|
| Infant | 5 | 2023 | 7946 | 0.200 |
Why?
|
| Mentors | 1 | 2023 | 155 | 0.200 |
Why?
|
| Career Choice | 1 | 2023 | 178 | 0.190 |
Why?
|
| Antifungal Agents | 1 | 2022 | 128 | 0.190 |
Why?
|
| Metagenomics | 1 | 2022 | 131 | 0.190 |
Why?
|
| Humans | 17 | 2023 | 114080 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 180 | 0.180 |
Why?
|
| Plasma | 1 | 2022 | 181 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2023 | 159 | 0.180 |
Why?
|
| Shock, Septic | 1 | 2023 | 185 | 0.180 |
Why?
|
| Bacterial Infections | 1 | 2023 | 217 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 64 | 0.180 |
Why?
|
| Disease Management | 2 | 2022 | 556 | 0.180 |
Why?
|
| Central Nervous System | 1 | 2022 | 230 | 0.180 |
Why?
|
| Hearing Loss | 1 | 2023 | 183 | 0.170 |
Why?
|
| Adolescent | 5 | 2022 | 17811 | 0.170 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 219 | 0.170 |
Why?
|
| Thyroiditis, Suppurative | 1 | 2019 | 1 | 0.170 |
Why?
|
| Candida tropicalis | 1 | 2019 | 2 | 0.170 |
Why?
|
| Thyroid Crisis | 1 | 2019 | 7 | 0.170 |
Why?
|
| Hospitals, Pediatric | 2 | 2020 | 478 | 0.160 |
Why?
|
| Candidiasis | 1 | 2019 | 51 | 0.160 |
Why?
|
| Cross Infection | 1 | 2021 | 194 | 0.160 |
Why?
|
| Advisory Committees | 1 | 2020 | 207 | 0.160 |
Why?
|
| Texas | 1 | 2019 | 188 | 0.160 |
Why?
|
| Bone Diseases | 1 | 2019 | 57 | 0.160 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 92 | 0.150 |
Why?
|
| Sensitivity and Specificity | 1 | 2022 | 1690 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2021 | 9121 | 0.150 |
Why?
|
| Risk Factors | 2 | 2021 | 8612 | 0.140 |
Why?
|
| Female | 7 | 2023 | 59349 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3007 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 256 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2023 | 12521 | 0.110 |
Why?
|
| Bile Ducts | 1 | 2014 | 68 | 0.110 |
Why?
|
| Hospitalization | 1 | 2022 | 1763 | 0.100 |
Why?
|
| Biliary Atresia | 1 | 2014 | 185 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 766 | 0.090 |
Why?
|
| Male | 6 | 2023 | 55420 | 0.080 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2008 | 66 | 0.070 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 109 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2007 | 158 | 0.070 |
Why?
|
| Young Adult | 1 | 2021 | 10459 | 0.070 |
Why?
|
| Bronchi | 1 | 2007 | 223 | 0.070 |
Why?
|
| Bronchodilator Agents | 1 | 2007 | 239 | 0.060 |
Why?
|
| Asthma | 2 | 2008 | 2021 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 493 | 0.060 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2023 | 16 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2465 | 0.050 |
Why?
|
| Haemophilus influenzae | 1 | 2023 | 48 | 0.050 |
Why?
|
| Neutrophils | 1 | 2008 | 1089 | 0.050 |
Why?
|
| Body Surface Area | 1 | 2023 | 27 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2023 | 48 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 59 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 143 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 143 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 133 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 131 | 0.050 |
Why?
|
| Adult | 2 | 2021 | 30395 | 0.050 |
Why?
|
| Hearing | 1 | 2023 | 131 | 0.050 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 148 | 0.050 |
Why?
|
| Animals | 2 | 2019 | 31570 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 76 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 150 | 0.040 |
Why?
|
| Thyroidectomy | 1 | 2019 | 62 | 0.040 |
Why?
|
| Body Weight | 1 | 2023 | 868 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 132 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2020 | 145 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 315 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 185 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 316 | 0.040 |
Why?
|
| Skin | 1 | 2023 | 653 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 246 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 347 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 2249 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2020 | 820 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2008 | 580 | 0.030 |
Why?
|
| Rotavirus | 1 | 2014 | 22 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 35 | 0.030 |
Why?
|
| Bilirubin | 1 | 2014 | 88 | 0.030 |
Why?
|
| Albumins | 1 | 2014 | 89 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2764 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 945 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 122 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2014 | 413 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1311 | 0.030 |
Why?
|
| Colorado | 1 | 2020 | 4092 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2014 | 719 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3397 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 687 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1128 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 960 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Leukocyte Elastase | 1 | 2007 | 71 | 0.020 |
Why?
|
| Spirometry | 1 | 2007 | 223 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 118 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 9051 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2007 | 316 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 496 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 3499 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 2550 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 14847 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 26621 | 0.000 |
Why?
|